These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Chemotherapy and immunotherapy in metastatic colorectal cancer. Copur MS; Norvell M; Obermiller A N Engl J Med; 2009 May; 360(20):2135; author reply 2135-6. PubMed ID: 19445033 [No Abstract] [Full Text] [Related]
4. Chemotherapy and immunotherapy in metastatic colorectal cancer. Loupakis F; Di Maio M; Falcone A N Engl J Med; 2009 May; 360(20):2135; author reply 2135-6. PubMed ID: 19445032 [No Abstract] [Full Text] [Related]
5. New combinations in metastatic colorectal cancer: what are our expectations? Hurwitz H Oncologist; 2005 May; 10(5):320-2. PubMed ID: 15851788 [No Abstract] [Full Text] [Related]
6. Antiangiogenesis drug promising for metastatic colorectal cancer. McCarthy M Lancet; 2003 Jun; 361(9373):1959. PubMed ID: 12801743 [No Abstract] [Full Text] [Related]
7. Bevacizumab plus oxaliplatin-based regimens for the treatment of colorectal cancer. Scheithauer W; Schmiegel W Onkologie; 2009 Jul; 32(7):431-9. PubMed ID: 19556824 [TBL] [Abstract][Full Text] [Related]
8. [Progress of chemotherapy in colorectal cancer]. Komatsu Y Gan To Kagaku Ryoho; 2007 Nov; 34(11):1771-6. PubMed ID: 18064761 [No Abstract] [Full Text] [Related]
9. Bevacizumab in colorectal cancer. Sharieff W N Engl J Med; 2004 Oct; 351(16):1690-1; author reply 1690-1. PubMed ID: 15490497 [No Abstract] [Full Text] [Related]
10. Should FOLFOXIRI plus bevacizumab Be the standard first-line therapy in metastatic colorectal cancer? Nipp RD; Ryan DP Oncologist; 2015 Mar; 20(3):236-8. PubMed ID: 25660156 [TBL] [Abstract][Full Text] [Related]
11. Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer. Dohn LH; Jensen BV; Larsen FO Acta Oncol; 2010 Apr; 49(3):395-6. PubMed ID: 20001495 [No Abstract] [Full Text] [Related]
13. Bevacizumab in colorectal cancer. Sonpavde G N Engl J Med; 2004 Oct; 351(16):1690-1; author reply 1690-1. PubMed ID: 15483292 [No Abstract] [Full Text] [Related]
14. Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. Graham CN; Hechmati G; Hjelmgren J; de Liège F; Lanier J; Knox H; Barber B Eur J Cancer; 2014 Nov; 50(16):2791-801. PubMed ID: 25219451 [TBL] [Abstract][Full Text] [Related]
15. Where to position monoclonal antibodies in first-line treatment of advanced colorectal cancer. Jackson C; Cunningham D Eur J Cancer; 2008 Mar; 44(5):652-62. PubMed ID: 18313913 [TBL] [Abstract][Full Text] [Related]
16. [Bevacizumab in the treatment of colorectal carcinoma: news from ASCO 2008]. Mansueto G; Longo F Tumori; 2008; 94(4):suppl 1-14. PubMed ID: 18822711 [No Abstract] [Full Text] [Related]
17. Current role of bevacizumab in colorectal cancer. Saltz L Clin Adv Hematol Oncol; 2009 Jun; 7(6):375-6. PubMed ID: 19606071 [No Abstract] [Full Text] [Related]
18. FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer. Giusti RM; Cohen MH; Keegan P; Pazdur R Oncologist; 2009 Mar; 14(3):284-90. PubMed ID: 19282350 [TBL] [Abstract][Full Text] [Related]
19. [Advances in the treatment of metastatic colorectal cancer with bevacizumab]. Longo F; Mansueto G Tumori; 2006; 92(5):suppl 1-12. PubMed ID: 17168449 [No Abstract] [Full Text] [Related]
20. The price tag on progress--chemotherapy for colorectal cancer. Schrag D N Engl J Med; 2004 Jul; 351(4):317-9. PubMed ID: 15269308 [No Abstract] [Full Text] [Related] [Next] [New Search]